Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - desferrioxamine mesilate, quantity: 500 mg - injection - excipient ingredients: - desferrioxamine mesilate is a binding agent for iron and aluminium. desferrioxamine mesilate is used to remove excess iron or aluminium from the body in patients with conditions such as iron poisoning, thalassemia (a heredity type of anemia) haemochromatosis (a disorder of iron metabolism) and aluminium overload due to kidney failure. it may also be used to diagnose iron storage disease and some types of chronic anemias or aluminium overload in some patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - desferrioxamine mesilate, quantity: 500 mg - injection, powder for - excipient ingredients: water for injections - a) acute iron intoxication. b) chronic iron overload due to transfusion-dependent anemias. c) diagnosis of aluminium overload (desferrioxamine infusion test). d) chronic aluminium overload in patients with esrf under maintenance dialysis. in cases of acute iron intoxication, desferrioxamine is an adjunct to, and not a substitute for, standard therapeutic measures whuich may include: i) induction of emesis. ii) gastric lavage. iii) maintenance of clear airways. iv) control of peripheral vascular failure. v) correction of acidosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - desferrioxamine mesilate, quantity: 500 mg - injection, powder for - excipient ingredients: - desferrixamine is used to promote iron excretion in patients with iron overload as a result of multiple blood transfusions. long term therapy with desferrioxamine slows accumulation of hepatic iron and retards or eliminated progression of hepatic fibrosis.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - desferrioxamine mesilate - powder for solution for injection - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - desferrioxamine mesilate - powder for solution for injection - 2gram

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - desferrioxamine mesilate, quantity: 2 g - injection, powder for - excipient ingredients: - chronic iron overload. desferrioxamine mesylate is used to promote iron excretion in patients with iron overload as a result of multiple blood transfusions frequently used in the treatment of some chronic anaemias and thalassaemia. long-term therapy with desferrioxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. patients under the age of 3 years with small degree of iron overload have relatively poor iron mobilisation with desferrioxamine mesylate. the drug is not normally given to such patients unless significant iron mobilisation of 1mg or more of iron per day can be demonstrated. desferrioxamine mesylate is not indicated for the treatment of primary haemochromatosis as phlebotomy is the method of choice for removing excess iron in this disorder. acute iron poisoning: desferrioxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron poisoning, which may include induction of emesis, gastric lavage, su

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - desferrioxamine mesilate, quantity: 500 mg - injection, powder for - excipient ingredients: - chronic iron overload. desferrioxamine mesylate is used to promote iron excretion in patients with iron overload as a result of multiple blood transfusions frequently used in the treatment of some chronic anaemias and thalassaemia. long-term therapy with desferrioxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. patients under the age of 3 years with small degree of iron overload have relatively poor iron mobilisation with desferrioxamine mesylate. the drug is not normally given to such patients unless significant iron mobilisation of 1mg or more of iron per day can be demonstrated. desferrioxamine mesylate is not indicated for the treatment of primary haemochromatosis as phlebotomy is the method of choice for removing excess iron in this disorder. acute iron poisoning: desferrioxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron poisoning, which may include induction of emesis, gastric lavage, su

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - desferrioxamine mesilate, quantity: 2 g - injection, powder for - excipient ingredients: - united kingdom iron overload - acute iron poisoning; primary and secondary haemochromatosis including thalassaemia and transfusional haemosiderosis; in patients in whom concomitant disorders (e.g. severe anaemia, hypoproteinaemia, renal or cardiac failure) preclude phlebotomy; and for the diagnosis of iron storage disease and certain anaemias. aluminium overload - in patients on maintenance dialysis for end stage renal failure where preventative measures (e.g. reverse osmosis) have failed and with proven aluminium-related bone disease and/or anaemia, dialysis encephalopathy; and for diagnosis of aluminium overload. canada a) acute iron intoxication b) chronic iron overlad due to transfusion dependent anemias c) diagnosis of aluminium overload d) chronic aluminium overload in patients with esrf under maintenance dialysis in cases of acute iron intoxication, desferrioxamine is an adjunct to, and not a substitute for, standard therapeutic measures which may include: i) induction of emesis ii) gastric lavage i

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - desferrioxamine mesilate - powder for solution for injection - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - desferrioxamine mesilate - powder for solution for injection - 2gram